Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin.
AML
Midostaurin
Neutropenic enterocolitis
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
11
08
2018
accepted:
12
11
2018
revised:
01
11
2018
pubmed:
7
12
2018
medline:
7
3
2019
entrez:
4
12
2018
Statut:
ppublish
Résumé
Neutropenic enterocolitis mostly affects patients with acute myeloid leukemia (AML) who get treated with intensive chemotherapy which is associated with prolonged neutropenia; its pathogenesis is not well understood and the main factors in this life-threatening condition appear to be neutropenia, mucosal injury and a weakened immune system as a consequence of intensive chemotherapeutic agents. Midostaurin in combination with chemotherapy became the standard of care for FLT3 mutant AML since its approval by the United States Food and Drug Administration (FDA) in April 2017. Anecdotally in our institution, we noticed the common occurrence of neutropenic colitis in three out of three patients who were treated with midostaurin as part of induction chemotherapy for AML.
Identifiants
pubmed: 30506467
doi: 10.1007/s12185-018-2558-4
pii: 10.1007/s12185-018-2558-4
doi:
Substances chimiques
FLT3 protein, human
EC 2.7.10.1
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
Staurosporine
H88EPA0A3N
midostaurin
ID912S5VON
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
351-355Références
Can J Surg. 1999 Dec;42(6):415-9
pubmed: 10593241
Cancer Invest. 2001;19(7):669-77
pubmed: 11577807
Blood. 2002 Jun 15;99(12):4326-35
pubmed: 12036858
Eur J Haematol. 2005 Jul;75(1):1-13
pubmed: 15946304
Cancer. 1990 Feb 15;65(4):1041-7
pubmed: 2404562
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114
AJR Am J Roentgenol. 1984 Oct;143(4):763-5
pubmed: 6332480